CD274 and melanoma: For instance, Patel, S.P. et al. proposed that during melanoma, lung, kidney, and other cancers, over 36% of patients with positive PD-L1 IHC expression responded to the PD-1/L1 axis-directed therapy, but approximately 17% of patients with a negative expression were also responded [12].